A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Thomas Jefferson University
Roswell Park Cancer Institute
Institute of Hematology & Blood Diseases Hospital, China
Prelude Therapeutics
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Thomas Jefferson University
Takeda
Massachusetts General Hospital
Janssen Research & Development, LLC
Massachusetts General Hospital
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Novartis
Thomas Jefferson University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Fujifilm Pharmaceuticals U.S.A., Inc.
M.D. Anderson Cancer Center
Stemline Therapeutics, Inc.
Heinrich-Heine University, Duesseldorf
Takeda
Astex Pharmaceuticals, Inc.
Astex Pharmaceuticals, Inc.
Astex Pharmaceuticals, Inc.
Astex Pharmaceuticals, Inc.
Kura Oncology, Inc.
Kirby Institute
M.D. Anderson Cancer Center
City of Hope Medical Center
Arbeitsgemeinschaft medikamentoese Tumortherapie
Fred Hutchinson Cancer Center
Pfizer
Pfizer
Stanford University
M.D. Anderson Cancer Center
Universitätsklinikum Hamburg-Eppendorf
Nanexa AB
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Albert Einstein College of Medicine
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Bristol-Myers Squibb
Rutgers, The State University of New Jersey
Prelude Therapeutics
M.D. Anderson Cancer Center
University of Rochester